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Abstract
Background: Prostate cancer is the most commonly diagnosed cancer in men and the second leading cause of
cancer death in men. Estrogen induction of cell proliferation is a crucial step in carcinogenesis of gynecologic
target tissues, and there are many studies recently done, showing that prostate cancer growth is also influenced
by estrogen. The characterization of estrogen receptor beta (ER-b) brought new insight into the mechanisms
underlying estrogen signalling. In the present study, we investigated the expression of estrogen receptor-b (ER-b)
in human prostate cancer tissues.
Methods: We selected 52 paraffin-embedded blocks of prostate needle biopsies in a cross-sectional study to
determine frequency and rate of ER-b expression in different grades of prostate adenocarcinoma according to
Gleason grading system. Immunohistochemical staining of tissue sections by monoclonal anti ER-b antibody was
performed using an Envision method visualising system.
Results: ER-b expression was seen in tumoral cells of prostatic carcinoma in all 29 cases with low and intermediate
tumors (100%) and 19 of 23 cases with high grade tumor (83%). Mean rate of ER-b expression in low &
intermediate grade cancers was 68.41% (SD = 25.63) whereas high grade cancers showed 49.48% rate of
expression (SD = 28.79).
Conclusions: ER-b expression is reduced in high grade prostate cancers compared to low & intermediate grade
ones (P value 0.027).
Background
Prostate cancer is the most common non-cutaneous
cancer among males and account for 10% of male cancer
deaths. Etiology of prostate cancer is mainly unclear but
seems to be multifactorial in origin such as alteration of
genes, diet, race and hormones [1-3]. Increasing age,
weight, and a fat-rich diet as potential risk factors for pros-
tate cancer may be associated with an increase in estrogen
levels or high estrogen/androgen levels in circulating
blood [4]. Both epidemiological and experimental data
suggest that estrogens are involved in prostatic cancer car-
cinogenesis and tumor progression [5]. Also since the pio-
neering work of Huggins and co-workers, estrogens have
been widely used in the medical treatment of hormone
refractory prostate cancer [6]. The role of estrogen in
prostate cancer progression is not well understood. It is
generally accepted that estrogens have influence on pro-
static growth indirectly through effects at the hypothala-
mic and pituitary levels, reducing gonadotrophin secretion
and hence the synthesis of testicular testosterone, but
effects of estrogens on target tissues are now known to be
mediated by ligand-specific receptor proteins termed
estrogen receptor-a and -b (ER-a and ER-b). In prostate,
ER-b is preferentially expressed in epithelial cells but ER-a
is found in stromal and basal cells [7]. There are evidences
of increased ER staining intensity in malignant prostate
[8]. ER-a and ER-b belong to the nuclear hormone recep-
tor family, many of whose members are ligand-activated
transcription factors that regulate gene expression in a
cell- and promoter-specific manner. Expression of estro-
gen receptors has been found in many other hormone-
dependent tumors such as uterus, breast, and also identi-
fied in lung cancer and a few brain tumors [9,10]. Most of
the physiologic effects of estrogen are attributed to its
activity at the ER-a receptor. Although ER-a and ER-b
have similar ligand-binding domains and both bind
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demonstrate distinct and sometimes opposing transcrip-
tional activities [11]. All the ERs are widely distributed.
ER-a receptors are found in endometrium, breast, ovary
and hypothalamus; whereas ER-b has been documented in
kidney, brain, skeleton, prostate and endothelial cells [12].
Previous studies using different methodologies have
provided evidences that ERs are present in various pro-
portions in normal prostate, prostatic cancer and dyspla-
sia [12]. The role of ER-b in pathogenesis or prognosis
of prostate cancer is unclear [4]. It seems to have a role
in the control of proliferation and the prevention of
hyperplasia in the rodent prostate, as ERb knockout
mice show prostatic hyperplasia in aging process. How-
ever, the regulatory impact of estrogens on normal and
abnormal prostatic growth still remains a matter of
great speculations [13].
In this study we examined estrogen receptor -b
expression in prostate adenocarcinoma by immunohisto-
chemichal study to determine its frequency and rate of
expression in different grades of tumor, defined by Glea-
son grading system.
Methods
52 Paraffin-embedded blocks of transrectal ultrasound
guided prostate needle biopsies diagnosed as prostate
carcinoma and related H&E (Haematoxylin and Eosin)
slides and pathology reports retrieved from archive of
pathology of “Hasheminejad Kidney Center”.A l lt h e5 2
specimens were judged by the pathologist to contain suf-
ficient tissue for immunohistochemichal analysis. None
of the patients had received any hormonal manipulation
before the needle biopsy. Tissue sections were cut 4 to 6
μm thick, stained by routine hematoxylin and eosin, and
reviewed by pathologist to confirm the diagnosis and re-
assign histologic grade according to Gleason grading sys-
tem criteria. The tumors categorized as “low grade” if
Gleason score was equal to or less than 4 and “high
grade” if Gleason score was equal to or more than 8.
Gleason score of 5, 6 and 7 was considered as intermedi-
ate grade. We considered low and intermediate grade as
one group if the score was less than 8. For immunohisto-
chemichal staining, tissue sections were deparaffinised,
and rehydrated. Heat-induced epitope retrieval was
achieved by boiling sections in the EDTA buffer at pH
8.9 in a high-pressure cooker for 20 minutes (4 × 5 min-
utes). Sections were allowed to cool at room temperature,
rinsed thoroughly with water, and placed in Tris-buffered
saline. Sections were incubated for 5 minutes with perox-
idase block solution (Envision; Dako, Glostrup, Denmark)
to neutralize endogenous peroxidases. Then sections
were incubated for 30 minutes at room temperature with
mouse anti-human ER-b; clone PPG5/10 (1:2 dilution;
Serotec, Oxford, UK). Immunostaining was performed
using the Envision method (Dako) according to the
manufacturer’s instructions. Appropriate positive and
negative controls were used. Estrogen receptor-b expres-
sion thoroughly sought for in tumoral cells as any nuclear
staining seen in tumoral cells. Etrogen receptor-b expres-
sion assigned as positive when more than 10% of tumoral
nuclei were stained. Rate of ER-b expression defined as
percentage of positive nuclei per 200 cells counted.
Statistical analysis was performed using SPSS 13.0
software. Chi square and Mann-Whitney U test were
used for comparative analysis.
Results
A total of 52 cases of prostatic adenocarcinoma were stu-
died including 29 low and intermediate grade cancers and
23 high grade cancers. Mean age of patients was 67 ± 8
(range:55-84). Using immunohistochemichal method and
10% nuclear staining as the cut off point, 48 prostate ade-
nocarcinoma expressed ER-b (92.3%) and 4 cases were
ER-b negative (7.7%) which all of them were high grade
cancers (Table 1). We found ER-b expression in tumoral
cells of prostate carcinoma in 29 of our low and inter-
mediate grade cancers (100%) and 19 of high grade can-
cers (83%) but 4 high grade cancers were negative (17%).
Considering percent of positive nuclei counted in 200
cells, the mean rate of ER-b expression in low & inter-
mediate grade cancers was 68.41% (SD = 25.63) whereas
high grade cancers showed 49.48% rate of expression (SD
= 28.79). (Figure 1, 2)
Discussion
We found ER-b expression in all of our low and inter-
mediate grade cancers and in 83% of high grade cancers
but 17% of high grade cancers were negative (P value
0.019). Our study reveals reduced expression of ER-b in
higher grade prostatic adenocarcinoma compared to low
& intermediate grade ones (P value 0.027).
In this study, we used immunohistochemichal staining
on paraffin-embedded blocks of prostate needle biopsy
for determining ER-b expression. Using prostate needle
biopsy specimen for immunohistochemichal studies of
prostate carcinoma has both advantages and disadvan-
tages. Considering the uniform thickness of specimens in
prostatic needle biopsies, tissue fixation is more rapid
and even in compare with prostatectomy specimens.
Table 1 Frequency of ER-b expression based on Gleason
score and tumor grade
Low & intermediate grade high grade total
Gleason grade 678 9 1 0
ER-b (+) 15 14 4 11 4 48
ER-b (-) 002 2 0 4
Total 15 14 6 13 4 52
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tions, such as missing focal small lesions in recut sec-
tions. An additional advantage of primary diagnostic
needle biopsy is that the patients usually have not
received any treatment before the biopsy.
Our data supports that rate of ER-b expression is sig-
nificantly lower in high grade tumors than in low &
intermediate ones (P value 0.027). These findings are
agreed with most of currently reported articles.
Leav.et al, using a different monoclonal anti ER-b anti-
body (anti GC-17), showed ER-b staining present in the
majority of grade 3 carcinomas of the peripheral zone
but greatly diminished or absent in most grade 4/5 car-
cinomas [14].
Lisa G. Horvath et al studied patterns of ER-b expres-
sion in normal, hyperplastic, and prostate carcinoma
using a different primary antibody (chicken polyclonal
antibody (ER-b 503 IgY3) for immuonohistochemistry.
In their study; all normal prostates showed strong ER-b
nuclear staining in > 95% of the epithelium and 35% of
the stromal cells. The number of ER-b positive cases
declined to 24.2% (38/157) in prostatic hyperplasia adja-
cent to carcinoma and 11.3% (18/159) in prostate
cancers. They conclude that ER-b is highly expressed in
normal human prostate and there is a progressive loss
of expression in prostatic hyperplasia and, to a greater
extent, in invasive cancer [15].
On the other hand, Bonkhoff et al, have tested two
commercially available antibodies in routinely processed
and frozen prostate carcinoma tissue sections. The 65-
kd anti-rat estrogen receptor b (Upstate Biotechnology,
Lake Placid, NY) and 210-180-C050 antibody (Alexis
Corporation, Nottingham, UK). They showed that low
and intermediate grade adenocarcinoma expressed ER-b
in a minority of cases and high grade (primary Gleason
grades 4 and 5) cancers revealed at least focal ER posi-
tivity in 43% (respectively 61%) of cases [4].
In 2003 Fixemer T. et al use a different monoclonal
antibody in immuonohistochemistry, reports higher ER-
b expression in cancer with Gleason grade IV than in
cancers with grades III and V and suggest that ER-b
protein expression decreases during cancer progression,
but no correlation was found between the ER-b status
and the primary Gleason grade [16].
I ts e e m st h e r ei sn oo b v i o u se x p l a n a t i o nf o rt h e s e
controversies between different reported results on the
levels of ER-b expression. It is well known that imper-
fect antibody specificity or different primary antibodies,
ineffective antigen retrieval and tissue-processing meth-
ods, or the presence of unknown isoforms of ER protein
may affect immuonohistochemistry performance. A pos-
sible implication of ER-b in neoplastic growth control is
suggested by the findings of a selective loss of ER-b pro-
tein in colon adenocarcinoma and ovarian cancer [17].
ER-b seems to have a role in the control of proliferation
and the prevention of hyperplasia in the rodent prostate,
as ER-b knockout mice show prostatic hyperplasia on
aging [13].
Conclusions
In summary we investigated ER-b expression in prostatic
adenocarcinoma with different grades and we found
reduced expression of ER-b in higher grade prostatic ade-
nocarcinoma compared to low & intermediate grade
ones. It seems more studies on influence of ER-b expres-
sion on prostate cancer staging and other prognostic fac-
tor would be more helpful to find the role of ER-b in
human prostate cancer. This observation may have clini-
cal implications as tumor cell expressing these protein
are potentially estrogen responsive and will survive in an
Figure 1 Prostate carcinoma Gleason score 3+3 showing >
70% positive nuclei stained by IHC for ER-b.
Figure 2 Cribriform architecture in a Gleason score 4+4
prostate carcinoma with negative immune reaction.
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for treating the cancer with anti-estrogens or not.
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